Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Surgery. 2013 Sep;154(3):545-55. doi: 10.1016/j.surg.2013.02.019. Epub 2013 Jun 15.
Although cirrhosis is common among Western hepatocellular carcinoma (HCC) patients, a substantial proportion are not cirrhotic. Studies examining surgical outcomes in noncirrhotic patients primarily evaluate Asian populations and liver resections. We describe cirrhotic and noncirrhotic HCC patients undergoing resection and transplantation at a Western institution.
We retrospectively reviewed 188 HCC patients treated surgically from 2000 to 2011 at a single Western institution. The primary endpoint was recurrence. Secondary endpoints included time to recurrence and overall survival.
We evaluated 138 cirrhotic and 50 noncirrhotic patients with a median follow-up of 33.8 months. Noncirrhotics mostly underwent liver resection (90%), whereas cirrhotics primarily underwent transplantation (67%). Hepatitis B was the most common underlying liver disease for noncirrhotics (64%), whereas hepatitis C (55%) and alcohol abuse (32%) predominated among cirrhotics. Pathologic evaluation demonstrated tumors in noncirrhotics that were fewer in number, larger, less differentiated, and more likely to have vascular invasion. Recurrence was more common for noncirrhotics (36 vs. 18%; P = .008) and more common after resection compared with transplantation. Overall median survival was 46.9 months for both groups. After resection, noncirrhotics had longer survival times than did cirrhotics (41.6 vs. 32.9 months; P = .04). Vascular invasion was an independent predictor for recurrence; tumor size was a predictor of mortality.
Noncirrhotics in our Western cohort had higher risk pathologic features, more frequently underwent resection, and suffered more recurrences than did cirrhotics. Overall survival was similar for both groups. Prospective studies of noncirrhotic HCC patients in Asia and Western countries may inform surveillance and treatment.
虽然肝硬化在西方肝细胞癌(HCC)患者中很常见,但相当一部分患者没有肝硬化。研究手术治疗非肝硬化患者的结果主要评估亚洲人群和肝切除术。我们描述了在西方机构接受肝切除和移植的肝硬化和非肝硬化 HCC 患者。
我们回顾性分析了 2000 年至 2011 年在一家西方机构接受手术治疗的 188 例 HCC 患者。主要终点是复发。次要终点包括复发时间和总生存时间。
我们评估了 138 例肝硬化和 50 例非肝硬化患者,中位随访时间为 33.8 个月。非肝硬化患者主要接受肝切除术(90%),而肝硬化患者主要接受肝移植(67%)。乙型肝炎是非肝硬化患者最常见的基础肝病(64%),而丙型肝炎(55%)和酒精滥用(32%)在肝硬化患者中更为常见。病理评估显示,非肝硬化患者的肿瘤数量较少、较大、分化程度较低且更有可能发生血管侵犯。非肝硬化患者的复发更为常见(36%比 18%;P=0.008),且与移植相比,更多见于肝切除术后。两组的中位总生存时间均为 46.9 个月。肝切除术后,非肝硬化患者的生存时间长于肝硬化患者(41.6 比 32.9 个月;P=0.04)。血管侵犯是复发的独立预测因素;肿瘤大小是死亡的预测因素。
在我们的西方队列中,非肝硬化患者具有更高风险的病理特征,更频繁地接受肝切除术,并且比肝硬化患者更容易复发。两组的总生存时间相似。亚洲和西方国家非肝硬化 HCC 患者的前瞻性研究可能会为监测和治疗提供信息。